

Erika Vacchelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1441930/erika-vacchelli-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

9,062
citations

51
h-index

88
g-index

88
ext. papers

10,622
ext. citations

9.2
avg, IF

5.5
L-index

#	Paper	IF	Citations
85	A loss-of-function polymorphism in compromises therapeutic outcome in head and neck carcinoma patients.. <i>Oncolmmunology</i> , 2022 , 11, 2059878	7.2	0
84	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021 , 11, 408-423	24.4	12
83	No impact of cancer and plague-relevant polymorphisms on COVID-19. <i>Oncolmmunology</i> , 2020 , 9, 1857142	7.2	2
82	Chemical activation of SAT1 corrects diet-induced metabolic syndrome. <i>Cell Death and Differentiation</i> , 2020 , 27, 2904-2920	12.7	11
81	Trial watch: TLR3 agonists in cancer therapy. <i>Oncolmmunology</i> , 2020 , 9, 1771143	7.2	23
80	Trial watch: STING agonists in cancer therapy. <i>Oncolmmunology</i> , 2020 , 9, 1777624	7.2	61
79	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmmunology</i> , 2020 , 9, 1777625	7.2	45
78	Autophagy-mediated metabolic effects of aspirin. <i>Cell Death Discovery</i> , 2020 , 6, 129	6.9	8
77	Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. <i>Oncolmmunology</i> , 2020 , 9, 1796002	7.2	25
76	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncolmmunology</i> , 2019 , 8, e1657375	7.2	38
75	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019 , 10, 1486	17.4	95
74	Contribution of annexin A1 to anticancer immunosurveillance. <i>Oncolmmunology</i> , 2019 , 8, e1647760	7.2	10
73	Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. <i>Oncolmmunology</i> , 2019 , 8, e1498285	7.2	14
72	TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. <i>Oncolmmunology</i> , 2018 , 7, e1462431	7.2	55
71	Organs on chip approach: a tool to evaluate cancer -immune cells interactions. <i>Scientific Reports</i> , 2017 , 7, 12737	4.9	54
70	The ratio of CD8/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma. <i>Oncolmmunology</i> , 2016 , 5, e1218106	7.2	39
69	Autophagy induction for the treatment of cancer. <i>Autophagy</i> , 2016 , 12, 1962-1964	10.2	44

68	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>OncolImmunology</i> , 2016 , 5, e1214790	7.2	51
67	Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. <i>Cancer Research</i> , 2016 , 76, 3122-6	10.1	42
66	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>OncolImmunology</i> , 2016 , 5, e1139275	7.2	17
65	Trial Watch-Immunostimulation with cytokines in cancer therapy. <i>OncolImmunology</i> , 2016 , 5, e1115942	7.2	35
64	Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. <i>OncolImmunology</i> , 2016 , 5, e1064581	7.2	11
63	Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. <i>OncolImmunology</i> , 2016 , 5, e1149673	7.2	99
62	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016 , 30, 147-160	24.3	285
61	Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. <i>OncolImmunology</i> , 2016 , 5, e1118600	7.2	14
60	Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate in vivo. <i>Cell Cycle</i> , 2015 , 14, 2399-407	4.7	22
59	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>OncolImmunology</i> , 2015 , 4, e1008866	7.2	162
58	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015 , 350, 972-8	33.3	267
57	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015 , 6, 588	8.4	239
56	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>OncolImmunology</i> , 2015 , 4, e985940	7.2	38
55	Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. <i>Oncotarget</i> , 2015 , 6, 20840-50	3.3	41
54	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. <i>OncolImmunology</i> , 2015 , 4, e988042	7.2	21
53	Regulation of autophagy by cytosolic acetyl-coenzyme A. <i>Molecular Cell</i> , 2014 , 53, 710-25	17.6	331
52	Trial Watch: Chemotherapy with immunogenic cell death inducers. <i>OncolImmunology</i> , 2014 , 3, e27878	7.2	116
51	Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014 , 20, 1301-9	50.5	596

50	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. <i>Oncolmunology</i> , 2014 , 3, e28344	7.2	30
49	Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. <i>Cell Death and Differentiation</i> , 2014 , 21, 59-68	12.7	66
48	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
47	Trial watch: Immunostimulatory cytokines in cancer therapy. <i>Oncolmunology</i> , 2014 , 3, e29030	7.2	47
46	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmunology</i> , 2014 , 3, e955691	7.2	524
45	Trial Watch: Toll-like receptor agonists in oncological indications. <i>Oncolmunology</i> , 2014 , 3, e29179	7.2	61
44	Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. <i>Oncolmunology</i> , 2014 , 3, e27048.2	7.2	64
43	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmunology</i> , 2014 , 3, e957994	7.2	166
42	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. <i>Oncolmunology</i> , 2014 , 3, e27297	7.2	86
41	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. <i>Oncolmunology</i> , 2014 , 3, e28473	7.2	83
40	Coffee induces autophagy in vivo. <i>Cell Cycle</i> , 2014 , 13, 1987-94	4.7	34
39	Regulation of autophagy by stress-responsive transcription factors. <i>Seminars in Cancer Biology</i> , 2013 , 23, 310-22	12.7	187
38	Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. <i>Immunity</i> , 2013 , 38, 729-41	32.3	439
37	Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. <i>Oncogene</i> , 2013 , 32, 4995-5004	9.2	80
36	Fluorescent biosensors for the detection of HMGB1 release. <i>Methods in Molecular Biology</i> , 2013 , 1004, 43-56	1.4	10
35	Crosstalk between ER stress and immunogenic cell death. <i>Cytokine and Growth Factor Reviews</i> , 2013 , 24, 311-8	17.9	106
34	Trial watch: DNA vaccines for cancer therapy. <i>Oncolmunology</i> , 2013 , 2, e23803	7.2	70
33	Current trends of anticancer immunochemotherapy. <i>Oncolmunology</i> , 2013 , 2, e25396	7.2	24

32	ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. <i>Oncolimmunology</i> , 2013 , 2, e24568	7.2	61
31	Trial watch: Cardiac glycosides and cancer therapy. <i>Oncolimmunology</i> , 2013 , 2, e23082	7.2	89
30	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. <i>Cell Cycle</i> , 2013 , 12, 417-214.7		24
29	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>Oncolimmunology</i> , 2013 , 2, e25771	7.2	87
28	Trial Watch: Lenalidomide-based immunochemotherapy. <i>Oncolimmunology</i> , 2013 , 2, e26494	7.2	39
27	Trial watch: Monoclonal antibodies in cancer therapy. <i>Oncolimmunology</i> , 2013 , 2, e22789	7.2	76
26	Trial watch: Chemotherapy with immunogenic cell death inducers. <i>Oncolimmunology</i> , 2013 , 2, e23510	7.2	72
25	Trial Watch: Peptide vaccines in cancer therapy. <i>Oncolimmunology</i> , 2013 , 2, e26621	7.2	84
24	Trial Watch: Adoptive cell transfer for anticancer immunotherapy. <i>Oncolimmunology</i> , 2013 , 2, e24238	7.2	43
23	Trial Watch: Immunostimulatory cytokines. <i>Oncolimmunology</i> , 2013 , 2, e24850	7.2	44
22	Trial Watch: Anticancer radioimmunotherapy. <i>Oncolimmunology</i> , 2013 , 2, e25595	7.2	75
21	Trial Watch: Toll-like receptor agonists for cancer therapy. <i>Oncolimmunology</i> , 2013 , 2, e25238	7.2	120
20	Trial watch: Oncolytic viruses for cancer therapy. <i>Oncolimmunology</i> , 2013 , 2, e24612	7.2	94
19	Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. <i>Cell Cycle</i> , 2012 , 11, 3851-60.7		79
18	Prognostic impact of vitamin B6 metabolism in lung cancer. <i>Cell Reports</i> , 2012 , 2, 257-69	10.6	100
17	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>Oncolimmunology</i> , 2012 , 1, 1111-1134	7.2	134
16	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncolimmunology</i> , 2012 , 1, 28-37	7.2	80
15	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. <i>Oncolimmunology</i> , 2012 , 1, 1323-1343	7.2	173

14	Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. <i>Science Translational Medicine</i> , 2012 , 4, 143ra99	17.5	266
13	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>Onc Immunology</i> , 2012 , 1, 894-907	7.2	163
12	Independent transcriptional reprogramming and apoptosis induction by cisplatin. <i>Cell Cycle</i> , 2012 , 11, 3472-80	4.7	31
11	Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. <i>Onc Immunology</i> , 2012 , 1, 271-278	7.2	33
10	Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. <i>Onc Immunology</i> , 2012 , 1, 1640-1642	7.2	73
9	Trial watch: Chemotherapy with immunogenic cell death inducers. <i>Onc Immunology</i> , 2012 , 1, 179-188	7.2	86
8	Trial watch: Peptide vaccines in cancer therapy. <i>Onc Immunology</i> , 2012 , 1, 1557-1576	7.2	73
7	Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. <i>Autophagy</i> , 2012 , 8, 413-5	10.2	74
6	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. <i>Onc Immunology</i> , 2012 , 1, 699-716	7.2	164
5	Trial Watch: Adoptive cell transfer immunotherapy. <i>Onc Immunology</i> , 2012 , 1, 306-315	7.2	58
4	Trial Watch: Immunostimulatory cytokines. <i>Onc Immunology</i> , 2012 , 1, 493-506	7.2	66
3	Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. <i>Science</i> , 2011 , 334, 1573-7	33.3	939
2	Cell death signaling and anticancer therapy. <i>Frontiers in Oncology</i> , 2011 , 1, 5	5.3	36
1	Mitochondrial gateways to cancer. <i>Molecular Aspects of Medicine</i> , 2010 , 31, 1-20	16.7	210